Literature DB >> 9414542

The diagnosis, management, treatment and costs of prostate cancer in England and Wales.

J Chamberlain1, J Melia, S Moss, J Brown.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9414542

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN： 1366-5278            Impact factor:   4.014


× No keyword cloud information.
  8 in total

1.  Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy.

Authors:  Betsan M Thomas; Christian Smith; Jessica Evans; Michael R Button; Satish Kumar; Nachi Palaniappan; John Staffurth; Jacob S Tanguay; Jason F Lester
Journal:  Med Oncol       Date:  2013-09-12       Impact factor: 3.064

2.  Dilemmas in treating early prostate cancer: the evidence and a questionnaire survey of consultant urologists in the United Kingdom.

Authors:  J L Donovan; S J Frankel; A Faulkner; S Selley; D Gillatt; F C Hamdy
Journal:  BMJ       Date:  1999-01-30

3.  Cost study of the clinical management of prostate cancer in France: results on the basis of population-based data.

Authors:  Laurent Molinier; Christel Castelli; Eric Bauvin; Xavier Rebillard; Michel Soulié; Jean-Pierre Daurès; Pascale Grosclaude
Journal:  Eur J Health Econ       Date:  2010-06-13

Review 4.  Symptomatic diagnosis of prostate cancer in primary care: a structured review.

Authors:  William Hamilton; Deborah Sharp
Journal:  Br J Gen Pract       Date:  2004-08       Impact factor: 5.386

5.  The economic burden of prostate cancer in Eswatini.

Authors:  Cebisile Ngcamphalala; Ellinor Östensson; Themba G Ginindza
Journal:  BMC Health Serv Res       Date:  2022-04-11       Impact factor: 2.655

Review 6.  Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies.

Authors:  Donatus U Ekwueme; Leonardo A Stroud; Yanjing Chen
Journal:  Prev Chronic Dis       Date:  2007-09-15       Impact factor: 2.830

7.  Effectiveness and cost-effectiveness of prognostic markers in prostate cancer.

Authors:  N W Calvert; A B Morgan; J W F Catto; F C Hamdy; R L Akehurst; P Mouncey; S Paisley
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

Review 8.  A review of tasquinimod in the treatment of advanced prostate cancer.

Authors:  Stuart Charles Williamson; Alice Elizabeth Hartley; Rakesh Heer
Journal:  Drug Des Devel Ther       Date:  2013-03-21       Impact factor: 4.162
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.